2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 2020, 21: 1317-1330. PMID: 32866432, PMCID: PMC7591827, DOI: 10.1016/s1470-2045(20)30452-6.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationProgression-free survivalStem cell transplantationVRd regimenInduction therapyMultiple myelomaVRd groupDay 1Oral lenalidomideOral dexamethasoneOverall survivalEastern Cooperative Oncology Group performance statusMedian progression-free survivalNon-haematological adverse eventsSecond planned interim analysisNext-generation proteasome inhibitorsHigh-risk multiple myelomaCommon grade 3Treatment-related deathsMedian overall survivalPhase 2 trialCommunity oncology practicesStandard of careKey inclusion criteriaPhase 3
2018
A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaNon-Hodgkin lymphomaOverall response rateIntermediate-grade B-cellB cellsPartial responseResponse ratePhase I dose-escalation studyRefractory acute lymphoblastic leukemiaI dose-escalation studyT-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaPositron emission tomography scanSecond-generation purine nucleoside analogAggressive B-cell lymphomasPhase IDose of clofarabineGrade 3 leukopeniaLow-dose cohortMinimal hematologic toxicityRefractory acute leukemiaRefractory low gradeRefractory lymphoid malignanciesSingle-agent rituximab
2015
Management of isolated calf vein thrombosis in cancer patients
Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2015, 24: 64-69. PMID: 25957344, DOI: 10.1177/1708538115584726.Peer-Reviewed Original ResearchConceptsCalf vein thrombosisIsolated calf vein thrombosisVein thrombosisHistory of cancerCancer patientsBenefits of anticoagulationInitiation of anticoagulationPatient risk factorsRetrospective chart reviewLong-term recurrenceChart reviewConsecutive patientsTreatment modalitiesRisk factorsThrombosisHigh incidencePatientsAnticoagulationOlder ageCancerMortalityIncidenceAnatomical characteristicsTreatmentRecurrence